Ibuprofen News and Research

RSS

Ibuprofen is a drug used to treat fever, swelling, pain, and redness by preventing the body from making a substance that causes inflammation. It is a type of nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.

Mental-health treatment could reduce pain in osteoarthritis patients: Study

How much pain osteoarthritis sufferers feel is directly related to their mental health, a new study by researchers at UC Davis School of Medicine has found. In the study, people with better mental health felt less pain, and people with worse mental health felt more.

31 Jul 2010

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Winston Laboratories receives NOC for CIVANEX

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Jul 2010

8.8% of drug-related hospital emergency department visits by adolescents is a suicide attempt

A new series of studies analyzing drug-related hospital emergency department visits throughout the country during 2008 reveals a substantial percentage of these visits involve suicide attempts. According to these studies conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA) more than one in every twelve (8.8 percent) drug-related hospital emergency department visit by an adolescent is a suicide attempt - double the rate found among cases involving those age 25 and older (4.4 percent).

15 Jul 2010

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

Cumberland Pharmaceuticals Inc. today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene. The study, which is the first to document an antipyretic effect of an injectable non-steroidal anti-inflammatory drug on fever caused by malaria, demonstrated that patients who received intravenous ibuprofen experienced a greater reduction in their temperatures than those who received placebo.

13 Jul 2010

Winston submits NDA for CIVANEX to U.S. FDA

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee.

7 Jul 2010

Use of NSAIDs do not increase risk of heart attack in elderly patients: Study

Commonly used painkillers like ibuprofen do not increase the risk of heart attack in the elderly population, according to a new study. Researchers found that the use of these drugs - also called non-steroidal anti-inflammatory drugs - was also associated with a lower risk of death although they are not sure why.

7 Jul 2010

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).

29 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

June issue of Clinic Women's HealthSource provides overview of anemia

Anemia is not a normal part of aging, yet it's fairly common in older adults and causes frailness, weakness and increased risk of falls. According to Mayo Clinic Women's HealthSource, more than one in 10 older adults has anemia. Twenty percent of women are anemic by age 85.

24 Jun 2010

Model Formulary for Children provides information on how to use over 240 essential medicines

The first ever WHO Model Formulary for Children released by the WHO provides information on how to use over 240 essential medicines for treating illness and disease in children from 0 to 12 years of age. This means that for the first time medical practitioners worldwide have access to standardized information on the recommended use, dosage, adverse effects, and contraindications of these medicines for use in children.

18 Jun 2010

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Horizon Pharma, Inc., announced today that data from the Phase 3 U.S. registration study of LODOTRA, a circadian cytokine modulator and novel modified-release, low-dose prednisone tablet, showed a statistically significant improvement in American College of Rheumatology response criteria in patients with rheumatoid arthritis.

16 Jun 2010

Topical NSAIDs are safe and effective for acute pain: Researchers

Gels, creams and sprays containing painkillers such as ibuprofen, diclofenac, ketoprofen, and piroxicam are safe and effective treatments for local pain, according to Cochrane Researchers. A new systematic review they have conducted shows that topical non-steroidal anti-inflammatory drugs are more effective than placebos for treating short-term pain and have few side effects.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Study assesses possible links between pain medications and recurrent breast cancer risk

Women who receive one common pain drug during mastectomy are less likely to develop recurrent breast cancer in the years following surgery, suggests a study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

27 May 2010

FDA accepts Horizon Pharma's DUEXA NDA for review

Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.

27 May 2010

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

PLx Pharma, a pharmaceutical company developing safer formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs), today announced that it has been awarded multiple grants from the National Institutes of Health (NIH) totaling approximately $2,000,000. This funding has been awarded to support further advancement of a range of products currently under development by PLx.

12 May 2010

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

12 May 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

6 May 2010

Ibuprofen News and Research

Further Reading

Mental-health treatment could reduce pain in osteoarthritis patients: Study

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Winston Laboratories receives NOC for CIVANEX

8.8% of drug-related hospital emergency department visits by adolescents is a suicide attempt

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

Winston submits NDA for CIVANEX to U.S. FDA

Use of NSAIDs do not increase risk of heart attack in elderly patients: Study

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

June issue of Clinic Women's HealthSource provides overview of anemia

Model Formulary for Children provides information on how to use over 240 essential medicines

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Topical NSAIDs are safe and effective for acute pain: Researchers

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Study assesses possible links between pain medications and recurrent breast cancer risk

FDA accepts Horizon Pharma's DUEXA NDA for review

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News